XM does not provide services to residents of the United States of America.
P
P

Pfizer

Trade Ideas

Traders Sentiment

Technical Summary

Hourly

News

What to Watch in the Week Ahead and on Monday, July 29

What to Watch in the Week Ahead and on Monday, July 29 The Day Ahead is an email and PDF publication that includes the day's major stories and events, analyses and other features. To receive The Day Ahead, Eikon users can register at DAY/US . Thomson One users can register at RT/DAY/US. All times in ET/GMT ON MONDAY McDonald's is expected to post a smaller growth in second-quarter revenue as customers cut back on dining out amid persistent inflation.
A
A
B
E
K
M
M
P
Q
S
S
E
K
C
L

Pfizer Inc <PFE.N> expected to post earnings of 46 cents a share - Earnings Preview

Pfizer Inc expected to post earnings of 46 cents a share - Earnings Preview Pfizer Inc PFE.N , PFE is expected to show a rise in quarterly revenue when it reports results on July 30 for the period ending June 30 2024 The New York City-based company is expected to report a 2.3% increase in revenue to $13.024 billion from $12.73 billion a year ago, according to the mean estimate from 15 analysts, based on LSEG data.
P

UK regulator authorises updated Pfizer-BioNTech COVID shot targeting JN.1 strain

UPDATE 1-UK regulator authorises updated Pfizer-BioNTech COVID shot targeting JN.1 strain Adds details in paragraphs 2 & 3 July 24 (Reuters) - Britain's health regulator said on Wednesday it has authorised Pfizer PFE.N and BioNTech's 22UAy.DE updated COVID-19 vaccine that targets the JN.1 subvariant for use in infants, children and adults. The Medicines and Healthcare products Regulatory Agency (MHRA) said it has approved four forms of the adapted Comirnaty JN.1 vaccine after reviewing its safet
P

UK regulator authorises Pfizer-BioNTech shot for JN.1 COVID variant

UK regulator authorises Pfizer-BioNTech shot for JN.1 COVID variant July 24 (Reuters) - Britain's health regulator said on Wednesday it has authorised Pfizer PFE.N and BioNTech's 22UAy.DE updated COVID-19 vaccine that targets the JN.1 subvariant of the coronavirus for use in infants, children and adults. Reporting by Unnamalai L in Bengaluru; Editi
P

UK's MHRA Approved An Adapted Pfizer/Biontech Covid-19 Vaccine (Comirnaty) That Targets The Jn.1 Covid-19 Subvariant

BRIEF-UK's MHRA Approved An Adapted Pfizer/Biontech Covid-19 Vaccine (Comirnaty) That Targets The Jn.1 Covid-19 Subvariant July 24 (Reuters) - UK's MHRA: UK'S MHRA: APPROVED AN ADAPTED PFIZER/BIONTECH COVID-19 VACCINE (COMIRNATY) THAT TARGETS THE JN.1 COVID-19 SUBVARIANT UK'S MHRA: FOUR FORMS OF THIS ADAPTED COMIRNATY JN.1 VACCINE HAVE BEEN APPROVE
P

Conditions

Popular Assets

Disclaimer: The XM Group entities provide execution-only service and access to our Online Trading Facility, permitting a person to view and/or use the content available on or via the website, is not intended to change or expand on this, nor does it change or expand on this. Such access and use are always subject to: (i) Terms and Conditions; (ii) Risk Warnings; and (iii) Full Disclaimer. Such content is therefore provided as no more than general information. Particularly, please be aware that the contents of our Online Trading Facility are neither a solicitation, nor an offer to enter any transactions on the financial markets. Trading on any financial market involves a significant level of risk to your capital.

All material published on our Online Trading Facility is intended for educational/informational purposes only, and does not contain – nor should it be considered as containing – financial, investment tax or trading advice and recommendations; or a record of our trading prices; or an offer of, or solicitation for, a transaction in any financial instruments; or unsolicited financial promotions to you.

Any third-party content, as well as content prepared by XM, such as: opinions, news, research, analyses, prices and other information or links to third-party sites contained on this website are provided on an “as-is” basis, as general market commentary, and do not constitute investment advice. To the extent that any content is construed as investment research, you must note and accept that the content was not intended to and has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such, it would be considered as marketing communication under the relevant laws and regulations. Please ensure that you have read and understood our Notification on Non-Independent Investment. Research and Risk Warning concerning the foregoing information, which can be accessed here.

Risk Warning: Your capital is at risk. Leveraged products may not be suitable for everyone. Please consider our Risk Disclosure.